Author Archive: Roy Zwahlen

Roy Zwahlen

Roy is Associate Counsel at BIO and the main contributor for Patently Biotech. He is a lawyer by training, with a background in international and national politics. He grew up in the developing world and believes that innovation can and does solve many of the world’s problems. Because of this, his work focuses on creating a worldwide policy environment that fosters innovation in the biotechnology sector to prevent and cure diseases such as HIV, to increase crop yields to feed more people, and to decrease the harmful effects of industry on the environment. Roy spends his free time keeping up with his three kids, a wife that knows everything (no joke), and serving in his church and broader community. Learn more about Roy from his Linkedin Profile.

Latest Posts

IP in Latin America: Growing Recognition of the Importance of IP to Innovation

Photo by Márcio Cabral de Moura

The Inter-American Dialogue’s daily Latin America Advisor recently asked the question “How seriously do Latin American countries protect IP rights?”  The editors asked various stakeholders about the U.S. Trade Representative’s Special 301 Report and its evaluation of Latin America’s protection of IP rights.  BIO’s Director for International Affairs, Meredith Fensom, commented on the growth of the innovative biotechnology sectors in Latin America and the critical role intellectual property plays.  ”The presence of more than 60 Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Gene Patents, Angelina Jolie, and Reality

Gene Patents, Angelina Jolie, and Reality

By Dr. Hans Sauer, J.D., Deputy General Counsel for Intellectual Property, Biotechnology Industry Organization  Angelina Jolie recently announced her personal connection with breast cancer and Myriad’s BRCA genetic test.  While Jolie’s post was a commendable personal account of the real world impact of breast cancer and the real world impact of developments in healthcare technology, a few less informed individuals have tried to take advantage of this recent announcement from stardom and spread misinformation.  Let’s Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , ,

Canada Patent Utility: Former USPTO Director Interview at BIO Convention

Photo credit to Meddy Garnet

David Kappos, former Director, US Patent and Trade Office and current Partner Cravath, Swaine and Moore, LLP discusses the Canadian Utility Requirement.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

What OxyContin Tells Us About the Value of “Evergreening” and Patents

Be.Futureproof

A few weeks ago, the  FDA announced that they would not allow generic versions of older versions of OxyContin. The original formulation of OxyContin goes off patent today. The original formulation did not have “tamper-resistant qualities” that prevent people from “crushing, breaking, and dissolution using a variety of tools and solvents.”  The article reports that the decision will keep Teva Pharmaceuticals and Impax Laboratories from making the older version which the FDA has determined is too dangerous Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO Members Receive Patents for Humanity Award

US Trade

The United States Patent and Trademark Office announced the winners of the Patents for Humanity awards. “The Patents for Humanity is a competition recognizing patent owners and licensees who address global challenges in health and standards of living.” The USPTO website provides this background on the BIO member winners: “Gilead Sciences “Of the 35 million people worldwide suffering from HIV, 95% live in developing countries. Gilead produces antiretroviral therapies for the treatment of HIV. They Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: ,